Investors are often drawn to social, technological, or economic trends that they think may o er lasting opportunities and the potential for investment returns. From e-commerce to big data to Chinese consumption, many durable themes have the potential to cause substantial asset repricing. In our opinion, prudent capital allocation compels asset owners to remain vigilant of such trends, given the potential for new risks and opportunities to arise over time.

Our global macroanalysis advisor o ers his top 10 list of books on the forces shaping geopolitics and policy today, from the rise of China to the threat of climate change.

One Of the challenges Of being a bOttOm-up investOr is that there are always mOre cOmpanies than yOu can pOssibly research. This is why, in an attempt to help my colleagues, I have tried to straddle micro and macro (call it mezza), keeping an eye on the aggre- gate equity markets and their dynamics as a subject on their own to see if there are things happening that are strange or noteworthy.

As the shift towArd electric vehicles (evs) And Autonomous vehicles (Avs) progresses, the potential impact on a variety of industries, and on the oil market, should come into sharper focus. Recently, several of Wellington’s global industry analysts debated and discussed these trends, and some of the issues they believe are underappreciated by many investors and economists.

Amid recent extreme weather events, many clients have asked for insights on climate change. Macroanalyst Spencer Glendon has spent several years researching climate science and writing about it for our investors. Here we share excerpts from a series of his notes to our rm.

Despite recent volatility, opportunities in health care remain abundant, and we believe the long-term outlook for the sector is positive. Powerful demographic trends, a record-setting pace of innovation, and structural changes in health care delivery systems continue to drive growth and expand the investment opportunity set. Wellington Management’s Health Care team currently manages over US$60 billion in assets for clients globally.1 Several team members recently shared their views on advances in the biopharmaceutical industry around the world.